

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Alan Michael CHAPMAN et al.

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Phenethanolamine Derivative for the
Treatment of Respiratory Diseases*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references listed on the attached form PTO-1449 as item nos. 6-7, 9-24, 30-37, 39 and 41 are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP2003/012035 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 8, 38 and 40 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert J. Smith
Attorney of Record
Registration No. 40,820

Date: April 26, 2005
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9616
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/532869	
				FILING DATE		To be assigned Concurrently herewith	
				APPLICANT		Alan Michael CHAPMAN et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PG4979USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	2,918,408	12/22/1959	BIEL			
	2.	4,778,054	10/18/1988	NEWELL et al.			
	3.	4,811,731	03/14/1989	NEWELL et al.			
	4.	5,035,237	07/30/1991	NEWELL et al.			
	5.	5,552,438	09/03/1996	CHRISTENSEN, IV			
Continue on page 2							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	6.	GB 2064336	06/17/1981	GB			X
	7.	GB 2129691	05/23/1984	GB			X
	8.	GB 2140800	12/05/1984	GB			X
	9.	DE35138885	10/17/1985	DE			X
	10.	EP 162576	11/27/1985	EPO			X
	11.	GB 2159151	11/27/1985	GB			X
	12.	DE3524990	01/23/1986	DE			X
	13.	GB 2165542	04/16/1986	GB			X
	14.	GB 2169265	07/09/1986	GB			X
	15.	GB 2178965	02/25/1987	GB			X
	16.	EP 220054	04/29/1987	EPO			X
Continue on page 2							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	17.	Augstein et al., "Aryloxyalkylaminoguanidines. Their synthesis and biological properties," <i>J. Med. Chem.</i> 10:391-400 (1967).					
	18.	Connon et al., "Recent developments in olefin cross-metathesis," <i>Angew. Chem. Int. Ed.</i> 42(17):1900-1923 (Apr. 2003).					
	19.	Fuji et al., "Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 284(1):162-169 (1998).					
	20.	Hett et al., "Large-scale synthesis of enantio- and diastereomerically pure (R,R)-formoterol," <i>Organic Process Research & Development</i> 2(2):96-99 (Mar. 1998).					
	21.	Kaiser et al., "Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential β -adrenergic agonists," <i>J. Med. Chem.</i> 20(5):687-692 (May 1977).					
	22.	Landells et al., "Oral administration of the phosphodiesterase (PED)4 inhibitor, V11294A inhibits ex-vivo agonist-induced cell activation," <i>Eur Resp J.</i> 12(Suppl. 28):Abst. P2393 CAS reference no. 162401-32-3 (Sep. 19-23 1998).					
	23.	LeClerc et al., "Synthesis and structure-activity relationships among α -adrenergic receptor agonists of the phenylethanolamine type," <i>J. Med. Chem.</i> 23(7):738-744 (1980).					
	24.	Sonesson et al., "An efficient synthesis of the novel dopamine autoreceptor antagonist S-(-)-OSU6162, via palladium catalyzed cross-coupling reaction," <i>Tet. Letts.</i> 35(48):9063-9066 (Nov. 1994).					
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

U.S. PATENT DOCUMENTS (Cont'd)

Continue on page _____

Continue on page _____

Continue on page

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	